Navigation Links
Sangamo BioSciences Reports Third Quarter 2013 Financial Results
Date:10/23/2013

porting Ceregene's Investigational New Drug (IND) applications. In addition, Sangamo acquired Ceregene's preclinical and clinical therapeutic programs including its ongoing double-blind, placebo-controlled Phase 2 trial to evaluate its NGF-AAV (CERE-110) in Alzheimer's disease and the proprietary needle device for brain delivery of AAV. The Company does not expect the acquisition, including the ongoing Phase 2 clinical trial, to have any impact on its financial guidance regarding 2013 operating expenses or yearend cash. 
  • Notice of Allowance for New Patent Application Covering Genome Modification Technology.  On August 14, Sangamo announced that the United States Patent and Trademark Office (USPTO) had issued a Notice of Allowance for the U.S. patent application (US 20110301073) entitled "Novel DNA-binding Proteins and Uses Thereof."  The claims cover core architectural aspects of engineered Transcription Activator-Like Effectors, or TALEs, which enable these proteins to be useful in potential therapeutic applications of genome editing or gene regulation and for the efficient use of the technology in biomedical research and plant applications. 
  • Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome. On July 17, Sangamo announced the publication of groundbreaking research using zinc finger DNA-binding protein (ZFP) technology to insert a gene that permanently "silences" the extra copy of chromosome 21, which is the root cause of Down syndrome (DS). This advance, accomplished in induced pluripotent stem cells (iPSCs) derived from DS patients, provides a model to study the basic biology of DS which may enable the development of drugs that can potentially rebalance the cellular processes and pathologies that are impacted by this disorder. 
  • Financial Guidance

  • Cash and Investments: Subsequent to its recent public offering of common stock, Sangamo expects that its c
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
    2. Sangamo BioSciences Proposes Public Offering Of Common Stock
    3. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
    4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
    5. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
    6. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
    7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
    8. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
    9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
    10. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
    11. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... Lyme Research Alliance (LRA), ... research at universities, today announced the awarding of seven ... treatment and cure for Lyme and other tick-borne diseases. ... applications in its history—over 20 grant proposals—a 100 percent ... pleased to receive so many solid applications from talented ...
    (Date:9/30/2014)... On September 11, Pharma IQ conducted an ... of a session that he will lead on “Stem Cells” ... February 17-18, 2015 in London. In the interview posted ... Sherley to respond to several questions on the current state ... stem cell toxicity, and future trends in the use of ...
    (Date:9/30/2014)... Canada (PRWEB) September 30, 2014 Back in ... on 500 square feet. per employee, which included space for ... back then.” says Jeff Howell, partner at Nidea Corporate ... firm in Toronto. “By the year 2000, however, 250 ... now seeing that number come down to 175 to 225 ...
    (Date:9/29/2014)... of diagnostics today, with imaging techniques like MRI ... NMR (nuclear magnetic resonance) increasing steeply over the ... resolution and quality still limit these techniques because ... is hyperpolarization, which involves injecting the patient with ... the distribution and fate of specific molecules in ...
    Breaking Biology Technology:Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3
    ... Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical ... has voluntarily filed a Form 15 with the Securities ... common stock under the Securities and Exchange Act of ... to file periodic and other reports under the Exchange ...
    ... vaccine is available now for testing worldwide, from Replikins ... the same Replikins peptide technology which provided the surprise ... outbreak/pandemic was on its way ( http://www.replikins.com ... vaccine is its rapid availability; the WHO, CDC and ...
    ... - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture ... announced that it has reached an agreement with AVAC ... of its Apo AIMilano candidate. AVAC is a private, ... stage commercial businesses that expand Alberta,s value-added industry. , ...
    Cached Biology Technology:Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide 2SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC 2SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC 3
    (Date:9/30/2014)... at the University of California, San Diego, have completed ... using a method that uses the pixels in an ... known as mesh-free simulation. , The researchers, led by ... at the Jacobs School of Engineering at UC San ... method at the CompIMAGE,14 conference in Pittsburgh this month. ...
    (Date:9/30/2014)... all have in common? Unlike most eukaryotic multicellular ... diploid, these organisms are all polyploid, meaning they have ... have 3 and 4 sets of chromosomes, respectively, and ... in fact most plant species are polyploid. Polyploidy, or ... but only recently, with the development of molecular tools, ...
    (Date:9/30/2014)... LA JOLLAJoseph Ecker, a Salk professor and Howard ... staff scientist, have been named recipients in the ... of Health (NIH) through the BRAIN (Brain Research ... in neuroscience. The grant, announced September 30, provides ... Salk scientists over three years. , The BRAIN ...
    Breaking Biology News(10 mins):First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Salk scientists receive $3 million for BRAIN Initiative grant 2
    ... February 24, 2012; Wiley-Blackwell, the scientific, technical, medical ... Inc., has launched two new interdisciplinary review publications: ... and Signaling . WIREs Developmental Biology ... produce a complex, fully patterned adult organism. Edited by ...
    ... different molecules in cancer is an effective way to ... the University of California, San Francisco (UCSF) have foundwork ... include drugs like Avastin. The two-target approach, ... as neuroendocrine pancreatic tumors, may have broad application for ...
    ... new study by the University of California, Berkeley, Wildlife ... for establishing marine protected areas in Madagascar that offers ... no-take zones to areas that would allow fishing. , ... climate, along with dependence on fisheries and marine resources, ...
    Cached Biology News:Wiley-Blackwell launches 2 interdisciplinary review titles in developmental and membrane biology 2Cancer therapy more potent when it hits 2 targets 2Cancer therapy more potent when it hits 2 targets 3Study IDs new marine protected areas in Madagascar 2
    ... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
    ... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
    ... Fluorescence Test Plate consists of an anodized ... Inert Organic Fluorescent Compounds embedded in polymerized ... on BioTeks FLx800 and Synergy Multi-Detection Readers. ... GLP compliance while reducing the need for ...
    ... Agarose and SYBR Safe DNA Gel Stain combo offers ... versus buying these same products separately ... ethidium bromide Eliminates risks ... DNA and RNA fragments from 100 bp to >30 ...
    Biology Products: